Yue Zhou

Yue Zhou

Auto-generated profile, based on publicly available information

Yue Zhou

Department of Pharmacy, Xindu District People’s Hospital of Chengdu, Chengdu, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
QYQing Yao
Qing Yao
YZYue Zhou
Yue Zhou
YYYanhui Yang
Yanhui Yang
LCLianjun Cai
Lianjun Cai
LXLihui Xu
Lihui Xu
PLP. Andy Li
P. Andy Li

14 October 2021 in Oncogenesis
Verified
Journal Article
Open access
PDF file
YLYujuan Liu
Yujuan Liu
JWJiyin Wang
Jiyin Wang
RYRuixiang Yang
Ruixiang Yang
YCYuning Cheng
Yuning Cheng
YZYue Zhou
Yue Zhou
XZXiaowei Zhang
Xiaowei Zhang
Golgi protein 73 (GP73) and alpha fetoprotein (AFP) serve as biomarkers for the diagnosis of hepatocellular carcinoma (HCC), and their serum levels correlate with patients’ outcomes. However, the mechanisms underlying these correlations are unknown. Here we show that GP73 increased the secretion of AFP through direct binding to AFP, thereby promoting the proliferation and metastasis of HCC cells that expressed AFP and its receptor (AFPR). Extracellular GP73 contributed to the proliferation and metastasis of HCC cells independent of AFP and AFPR. Moreover, extracellular AFP and GP73 synergized to enhance the malignant phenotype of HCC cells. Furthermore, extracellular GP73 and AFP inhibited the antitumor effects of sorafenib and synergistically increased the drug resistance of HCC cells. These findings, which reveal the mechanism of GP73-mediated secretion of AFP and its effects on the malignant phenotype of HCC cells, provide a comprehensive theoretical basis for the diagnosis and treatment of HCC and identify potential drug targets.

25 June 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XLXiaoying Liu
Xiaoying Liu
YZYue Zhou
Yue Zhou
HWHaichuan Wang
Haichuan Wang
The most prevalent primary brain tumors in adults are gliomas. In addition to insufficient therapeutic alternatives, gliomas are fatal mostly due to the rapid proliferation and continuous infiltration of tumor cells into the surrounding healthy brain tissue. According to a growing body of research, aerobic glycolysis, or the Warburg effect, promotes glioma development because gliomas are heterogeneous cancers that undergo metabolic reprogramming. Therefore, addressing the Warburg effect might be a useful therapeutic strategy for treating cancer. Lactate plays a critical role in reprogramming energy metabolism, allowing cells to rapidly access large amounts of energy. Lactate, a byproduct of glycolysis, is therefore present in rapidly proliferating cells and tumors. In addition to the protumorigenesis pathways of lactate synthesis, circulation, and consumption, lactate-induced lactylation has been identified in recent investigations. Lactate plays crucial roles in modulating immune processes, maintaining homeostasis, and promoting metabolic reprogramming in tumors, which are processes regulated by the lactate-induced lactylation of the lysine residues of histones. In this paper, we discuss the discovery and effects of lactylation, review the published studies on how protein lactylation influences cancer growth and further explore novel treatment approaches to achieve improved antitumor effects by targeting lactylation. These findings could lead to a new approach and guidance for improving the prognosis of patients with gliomas.